Commercial
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.

Dr Reddy’s Wants To Break Into Top Five In India
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Companies
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Companies
Beam And Verve Benefit From Buzz Around Base-Editing Therapies
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
The Top Five (Non-COVID) Pharma Stories Of 2020
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
The Race To Vaccinate The World Against COVID-19
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.
Another Failure For Biohaven’s Troriluzole
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
GSK Aims To Launch 13 Blockbusters In Five Years
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Deals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Deals
The Top Five (Non-COVID) Pharma Stories Of 2020
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Strategy
Investors Animated Over Aclaris Oral Rheumatoid Arthritis Therapy
Great progress has been made in the treatment of RA with biologics and JAK inhibitors but there is a space for effective small-molecule therapies and Aclaris hopes to fill it with ATI-450.
The Top Five (Non-COVID) Pharma Stories Of 2020
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
RedHill On The Rise With Three Drugs And Potential COVID-19 Therapy
The Israeli biotech which is listed on the NASDAQ is in for a busy 2021 with strong marketing pushes for Movantik, Aemcolo and Talicia and completing a pivotal trial for COVID-19 hopeful opaganib.
Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
J.P. Morgan Day 4: Setting Goals For The Year Ahead
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.
Market Access
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
Multinationals Start 2021 Empty Handed In China National Reimbursement Race
China's latest round of reimbursement decisions show multinationals including AstraZeneca, BMS and Roche won’t be receiving national coverage for their latest immuno-oncology drugs any time soon.
TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS
The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.
Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Market Intelligence
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Intelligence
COVID-19 Could Change Attitudes To Flu, Bolster Xofluza
Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.
Roche's Phesgo Could Reduce Healthcare Costs In EU
Roche’s Phesgo may lower healthcare costs in Europe for treating breast cancer following its approval by European Commission. Other just-approved products nearing the EU market are ViiV’s Vocabria, to be used with Janssen’s Rekambys/Edurant, as a long-acting injectable HIV therapy, and Aimmune’s peanut allergy therapy, Palforzia.
Janssen's Tremfya Gains Psoriatic Arthritis Indication In EU
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.